Lexaria Bioscience (LEXX) Research & Development (2017 - 2026)
Lexaria Bioscience (LEXX) posted Research & Development of $970834.0 for Q2 2026, up 104.22% sequentially from $475388.0 in Q1 2026, and down 64.27% YoY from $2.7 million in Q2 2025.
Lexaria Bioscience (LEXX) Research & Development (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Research & Development for 10 years, with the latest figure at $970834.0 in Q2 2026.
- Quarterly Research & Development fell 64.27% year-over-year to $970834.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $4.0 million (down 45.39% YoY) and the FY2025 annual result came in at $8.2 million, up 249.02% from the prior year.
- Research & Development improved to $970834.0 in Q2 2026 per LEXX's latest filing, from $475388.0 in the prior quarter.
- Over five years, Research & Development peaked at $2.7 million in Q2 2025 and troughed at $245779.0 in Q1 2024.
- A 5-year average of $987087.4 and a median of $724136.5 in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2025 and 2026: Research & Development surged 585.95% in 2025, then tumbled 71.8% in 2026.
- Over 5 years, Research & Development stood at $829489.0 in 2022, then sank by 30.74% to $574491.0 in 2023, then surged by 239.99% to $2.0 million in 2024, then tumbled by 65.63% to $671340.0 in 2025, then soared by 44.61% to $970834.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $970834.0, $475388.0, and $671340.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Lexaria Bioscience | 10.63 Mn | 7.01 Mn | - | 970,834.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 970,834.00 |
| Feb 28, 2026 | 475,388.00 |
| Nov 30, 2025 | 671,340.00 |
| Aug 31, 2025 | 1.88 Mn |
| May 31, 2025 | 2.72 Mn |
| Feb 28, 2025 | 1.69 Mn |
| Nov 30, 2024 | 1.95 Mn |
| Aug 31, 2024 | 967,206.00 |
| May 31, 2024 | 573,089.00 |
| Feb 29, 2024 | 245,779.00 |
| Nov 30, 2023 | 574,491.00 |
| Aug 31, 2023 | 500,406.00 |
| May 31, 2023 | 1.64 Mn |
| Feb 28, 2023 | 696,178.00 |
| Nov 30, 2022 | 829,489.00 |
| Aug 31, 2022 | 356,188.00 |
| May 31, 2022 | 752,095.00 |
| Feb 28, 2022 | 275,686.00 |
| Nov 30, 2021 | 458,709.00 |
| Aug 31, 2021 | 439,793.00 |